Stanczak Michal A, Läubli Heinz
The Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, 21287, USA.
Laboratory for Cancer Immunotherapy, Department of Biomedicine, University of Basel, Division of Oncology, University Hospital Basel, Switzerland.
Mol Aspects Med. 2023 Apr;90:101112. doi: 10.1016/j.mam.2022.101112. Epub 2022 Aug 7.
Cancer immunotherapy in the form of immune checkpoint inhibitors and cellular therapies has improved the treatment and prognosis of many patients. Nevertheless, most cancers are still resistant to currently approved cancer immunotherapies. New approaches and rational combinations are needed to overcome these resistances. There is emerging evidence that Siglec receptors could be regarded as new immune checkpoints and targets for cancer immunotherapy. In this review, we summarize the experimental evidence supporting Siglec receptors as new immune checkpoints in cancer and discuss their mechanisms of action, as well as current efforts to target Siglec receptors and their interactions with sialoglycan Siglec-ligands.
以免疫检查点抑制剂和细胞疗法形式存在的癌症免疫疗法已经改善了许多患者的治疗和预后。然而，大多数癌症对目前已获批的癌症免疫疗法仍然具有抗性。需要新的方法和合理的联合疗法来克服这些抗性。越来越多的证据表明，唾液酸结合免疫球蛋白样凝集素（Siglec）受体可被视为癌症免疫疗法的新免疫检查点和靶点。在这篇综述中，我们总结了支持Siglec受体作为癌症中新免疫检查点的实验证据，并讨论了它们的作用机制，以及目前针对Siglec受体及其与唾液酸糖Siglec配体相互作用的研究进展。
